Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-19
2011-07-19
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S458000, C514S474000, C514S561000, C514S562000, C514S570000, C514S722000
Reexamination Certificate
active
07981915
ABSTRACT:
This invention features methods for treating diseases associated with mutations in the CFTR gene by administering PPAR agonists, specifically PPARγ, PPARα, and PPARδ agonists, PPAR inducers, and/or antioxidants. Also disclosed are screening methods for identifying therapeutically useful candidate compounds.
REFERENCES:
patent: 5436269 (1995-07-01), Yazawa et al.
patent: 5925657 (1999-07-01), Seed et al.
patent: 5993221 (1999-11-01), Bistrian
patent: 6180671 (2001-01-01), Freedman et al.
patent: 6384065 (2002-05-01), Chaki et al.
patent: 6492425 (2002-12-01), Callahan et al.
patent: 6525083 (2003-02-01), Acton, III et al.
patent: 6552081 (2003-04-01), Freedman et al.
patent: 2003/0186215 (2003-10-01), Kishimoto et al.
patent: 2005/0101581 (2005-05-01), Reading et al.
patent: 2005/0134859 (2005-06-01), Kalayeh et al.
patent: 2006/0127491 (2006-06-01), Puder et al.
patent: 2010/0256235 (2010-10-01), Puder et al.
patent: 0682878 (1995-11-01), None
patent: 1133294 (2010-08-01), None
Chambrier et al., “Eicosapentaenoic Acid Induces mRNA Expression of Peroxisome Proliferator-Activated Receptor y,”Obes. Res. 10(6):518-525 (2002).
Davies et al., “Unique Ability of Troglitazone to Up-Regulate Peroxisome Proliferator-Activated Receptor-y Expression in Hepatocytes,”J. Pharmacol. Exp. Ther. 300(1):72-77 (2002).
De Vizia et al., “Effect of an 8-Month Treatment with Omega-3 Fatty Acids (Eicosapentaenoic and Docosahexaenoic) in Patients with Cystic Fibrosis,”J. Parenter. Enteral. Nutr. 27(1):52-57 (2003) (abstract only).
de Vries et al., “Haplotype Identity Between Individuals Who Share a CFTR Mutation Allele ‘Identical by Descent’: Demonstration of the Usefulness of the Haplotype-Sharing Concept for Gene Mapping in Real Populations,”Human Genetics98(3):304-309 (1996).
de Vries et al., “Haplotype Identity Between Individuals Who Share a CFTR Mutation Allele Identical by Descent: Demonstration of the Usefulness of the Haplotype Sharing Concept for Gene Mapping in Real Populations,” Chapter 6 (pp. 71-82) of Dissertation of de Vries, “Application of Molecular Techniques in Population Genetic Studies of Cystic Fibrosis in the Netherlands,” Rijksuniveriteit Groningen (1996).
Dubuquoy et al., “Role of Peroxisome Proliferator-Activated Receptor y and Retinoid X Receptor Heterodimer in Hepatogastroenterological Diseases,”Lancet360(9343):1410-1418 (2002).
Freedman et al., “A Membrane Lipid Imbalance Plays a Role in the Phenotypic Expression of Cystic Fibrosis in cftr-/-Mice,”Proc. Natl. Acad. Sci. U.S.A. 96(24):13995-14000 (1999).
Hotson, “Mutations to the CFTR Protein,”Bioinformatics 118, Final Reports for 2000, Stanford University (2000).
Huang et al., “The Pathophysiological Function of Peroxisome Proliferator-Activated-Receptor-y in Lung-Related Diseases,”Respir. Res. 6(1):102-110 (2005).
Printout from http://www.oml.gov/sci/techresources/Human—Genome/posters/chromosome/cftr.shtml “CTFR: The Gene Associated with Cystic Fibrosis” (2003), printed Aug. 9, 2007.
International Preliminary Report on Patentability for International Patent Application No. PCT/US04/13412, issued Nov. 4, 2005.
International Preliminary Report on Patentability for International Patent Application No. PCT/US06/42474, issued May 6, 2008.
International Search Report for International Patent Application No. PCT/US04/13412, mailed Oct. 29, 2004.
International Search Report for International Patent Application No. PCT/US06/42474, mailed May 10, 2007.
Naruse et al., “CFTRGene Mutation and Chloride Channel Dysfunction in Chronic Pancreatitis: From Gene to Clinics?,”J. Pancreas2(5 Suppl.): 332 (2001).
Nguyen et al., “The PPAR Activator Docosahexaenoic Acid Prevents Acetaminophen Hepatotoxicity in Male CD-1 Mice,”Journal of Toxicology and Environmental Health, Part A58:171-186 (1999).
Ockenga et al., “Mutations of the Cystic Fibrosis Gene, but not Cationic Trypsinogen Gene, Are Associated with Recurrent or Chronic Idiopathic Pancreatitis,”Am. J. Gastroenterol. 95(8):2061-2067 (2000) (abstract only).
Ollero et al., “Decreased Expression of Peroxisome Proliferator Activated Receptor Gamma in cftr-l-Mice,” J. Cell Physiol. 200(2):235-244 (2004).
Schroeder et al., “Protection Against Bronchial Asthma by CFTR Δ F508 Mutation: A Heterozygote Advantage in Cystic Fibrosis,”Nat. Med. 1(7):703-705 (1995) (abstract only).
Singer and Richter-Heinrich, “Stress and Fatty Liver—Possible Indications for Dietary Long-Chain n-3 Fatty Acids,” Medical Hypotheses 36:90-94, (1991).
Wood et al., “Improved Antioxidant and Fatty Acid Status of Patients with Cystic Fibrosis after Antioxidant Supplementation Is Linked to Improved Lung Function,”Am. J. Clin. Nutr. 77:150-159, (2003).
Written Opinion of the International Searching Authority for International Patent Application No. PCT/US04/13412, mailed Oct. 29, 2004.
Written Opinion o the International Searching Authority for International Patent Application No. PCT/US06/42474, mailed May 10, 2007.
Beth Israel Deaconess Medical Center
Bieker-Brady Kristina
Clark & Elbing LLP
Henley, III Raymond J
LandOfFree
Methods for modulating PPAR biological activity for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating PPAR biological activity for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating PPAR biological activity for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641192